Inverted chimeric RNAi molecules synergistically cotarget MYC and KRAS in KRAS-driven cancers.

J Clin Invest · 2025 · PMC12483557 · PMID 40762837

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Consistent with potent on-target regulation, treatment with MYC siRNAs resulted in a 54% reduction in MYC IHC staining, and MYC/KRAS inverted chimeric siRNAs resulted in a highly significant 76% reduction ( Figure 7D ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.